# A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

> **NCT03201718** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 505 (actual)

## Conditions studied

- Hepatitis C Virus (HCV)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03201718
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-17
- **Primary completion:** 2019-10-11
- **Final completion:** 2019-10-11
- **Target enrollment:** 505 (ACTUAL)
- **Last updated:** 2020-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03201718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03201718, "A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03201718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*